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Abstract
Background: An association between chronic obstructive pulmonary disease (COPD) and tuberculosis (TB) has
been described, mainly due to smoking and corticosteroid use. Whether inhaled corticosteroid (ICS) therapy is
associated with an increased risk of TB remains unclear.
Methods: We selected COPD cases by using six diagnostic scenarios and control subjects from a nationwide health
insurance database, and applied time-dependent Cox regression analysis to identify the risk factors for TB.
Results: Among 1,000,000 beneficiaries, 23,594 COPD cases and 47,188 non-COPD control subjects were selected.
Cox regression analysis revealed that age, male gender, diabetes mellitus, end-stage renal disease, and cirrhosis, as
well as COPD (hazard ratio = 2.468 [2.205–2.762]) were independent risk factors for TB. Among the COPD cases,
those who developed TB received more oral corticosteroids and oral β-agonists. Time-dependent Cox regression
analysis revealed that age, male gender, diabetes mellitus, low income, oral corticosteroid dose, and oral β-agonist
dose, but not ICS dose, were independent risk factors for TB. The identified risk factors and their hazard ratios were
similar among the COPD cases selected using different scenarios.
Conclusion: Keeping a high suspicion and regularly monitoring for the development of pulmonary TB in COPD
patients are necessary, especially for those receiving higher doses of oral corticosteroids and other COPD
medications. Although ICS therapy has been shown to predispose COPD patients to pneumonia in large
randomized clinical trials, it does not increase the risk of TB in real world practice.
Keywords: Chronic obstructive pulmonary disease, Tuberculosis, Inhaled corticosteroid, Oral corticosteroid,
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Background
Tuberculosis (TB) is a major cause of death worldwide.
The World Health Organization estimated that there
were 8.7 million new cases of TB in 2011 [1]. The risk
factors for TB included age, male gender, low socioeco-
nomic status, malnutrition, substance abuse, silicosis,
human immunodeficiency virus infection, malignancy,
diabetes, renal disease, celiac disease, gastrectomy, trans-
plant, and receiving corticosteroids and tumor necrosis
factor inhibitors [2-7]. In addition, an association between
obstructive pulmonary disorders (i.e. chronic obstructive
pulmonary disease [COPD] and asthma) and active TB
has been described, mainly due to smoking and cortico-
steroid use [7].
COPD is an airway inflammatory disease with a high
prevalence rate worldwide [8], ranging from 8.2% in China,
10.9% in Japan, 19.6% in USA, 23.8% in South Africa to
26.1% in Australia [9-13], It is a major health burden both
in developed and developing countries. Inhaled corticoste-
roids (ICS), along with long-acting β-agonists (LABA), are
currently recommended for patients with severe COPD
with repeated exacerbations [8]. ICS therapy has been
shown to predispose COPD patients to pneumonia in large
randomized clinical trials [14,15]. Causative microorganisms
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of pneumonia, however, were not described. Although the
systemic administration of corticosteroids is a known risk
factor for TB [7], whether ICS therapy is associated with an
increased risk of TB has yet to be elucidated.
A previous study on patients with COPD confirmed
by pulmonary function testing suggested that the use of
high-dose ICS, defined as an equivalent fluticasone
dose >500 μg per day, is associated with the development
of pulmonary TB in endemic areas of TB [16]. A nested
case–control study using a cohort of patients with airways
disease in the Quebec database also revealed that exposure
to ICS was associated with an increased risk of TB in
patients not receiving oral corticosteroids [17]. In both
studies, the results of Cox regression analysis may not
truly reflect the impact of ICS exposure, as time-dependent
analysis for the variable intensity of exposure was not
performed and the consumption of respiratory medications
other than ICS and oral corticosteroids (OCS) was not
considered. In addition, due to a lack of data on pulmonary
function testing, the severity of airway obstruction was not
determined and stratified in the latter study.
The National Health Insurance (NHI) program of Taiwan
is a mandatory universal health insurance program, offering
comprehensive medical care coverage to more than 95% of
the residents of Taiwan since 1996 [18]. In this study, we
used the NHI database and applied time-dependent Cox
proportional hazards models to identify the risk factors for
developing active pulmonary TB with a special emphasis
on the influence of COPD and its medications.
Methods
The Institutional Review Board of National Taiwan
University Hospital, Taipei, Taiwan approved the study
and waived the need for informed consent due to the
retrospective design (NTUH IRB: 201106091RC). The
study comprised of two parts. First, COPD cases and
control subjects matched in age (within 5 years), sex
and timing of entering the database were selected
(1:2 in case numbers) from the Longitudinal Health
Insurance Database (LHID) 2005, a subset database of
the NHI program. The characteristics of the LHID
2005 have been described previously [19]. We studied
the influence of COPD as well as other co-morbidities
on the risk of developing TB. In the second part of the
study, the effect of COPD medications on the risk of
developing TB was investigated with a time-dependent
approach among patients with COPD. All selected
cases were followed until commencement of anti-TB
treatment, December 31, 2007, or lost to follow-up
(canceled health insurance prior to December 31, 2007).
Selection criteria of COPD
Because of the wide spectrum of the clinical presentation
of COPD, the ambulatory care and inpatient discharge
records were analyzed to identify COPD patients from
1996 to 2007 using six different selection scenarios
combining diagnostic code, duration and interval of
medical visits with compatible diagnoses, prescriptions,
and age of onset. The selection scenarios of COPD started
from a loose criteria and gradually narrowed down to se-
vere COPD requiring multiple medications and out-patient
visits (scenarios 1 – 6 in Figure 1). The compatible COPD
diagnoses included International Classification of Diseases,
ninth revision, clinical modification (ICD-9-CM) codes
490–492, and 496, and A-code A323, A325. Prescriptions
for COPD were defined as at least two COPD-specific
medications or one COPD-specific medication plus at least
one airway medication(s) during a period of 90 days.
The COPD-specific medications included prescriptions
containing corticosteroids (inhaled, oral or parenteral),
β-agonists (long-acting or short-acting; inhaled or oral),
anti-cholinergics (ipratropium or tiotropium), aminophyl-
line, and theophylline. Airway medications included oral
antitussives, mucolytic agents, and sympathomimetics.
Patients who developed active TB prior to or within
180 days following the onset of COPD were excluded.
The number of selected COPD cases in each scenario
and the subsequent events of active TB during follow-up
are shown in Figure 1. The index date was defined as
the date of first visit or admission with a compatible
diagnosis for the COPD cases, and the corresponding
date after entering the LHID 2005 database for the
control subjects. COPD patients with an index date prior
to January 1, 1997 were excluded to ensure an observation
period of one year to monitor active TB treatment or
diagnosis. Patients with a follow-up duration of less
than six months after the index date were also excluded
to ensure a sufficient observation period to confirm the
subsequent development of TB.
Acute exacerbations (AEs) of COPD were defined as
emergency department visits or admissions with compatible
COPD diagnosis codes, plus a prescription of systemic
corticosteroids. An exacerbation occurring within 7 days
following a prior AE was considered as a continuation of
the prior episode.
Definition of active TB
Based on our previous publication [19], active TB was
defined by at least two ambulatory visits or one inpatient
record with a compatible diagnosis (ICD-9-CM codes
010–012, and 018, and A-codes A020, A021), plus at
least one prescription consisting of three or more than
three anti-tuberculous drugs. There should be prescriptions
of at least two anti-tuberculous drugs simultaneously
for 120 days or more during a period of 180 days. The
anti-tuberculous drugs included isoniazid, rifampicin,
ethambutol, pyrazinamide, prothionamide, terizidone,
streptomycin, kanamycin, quinolones, cycloserine, and
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Figure 1 Study flow chart. The number of chronic obstructive pulmonary disease (COPD) cases identified under different selection scenarios
and the number of subsequent tuberculosis (TB) cases.
Lee et al. BMC Infectious Diseases 2013, 13:194 Page 3 of 11
http://www.biomedcentral.com/1471-2334/13/194
aminosalicylic acid. For patients with end-stage renal
disease, the prescriptions were adjusted according to
treatment guidelines [20]. The TB notification rates
using these diagnostic criteria for each COPD selection
scenario are shown in Figure 1. The number of TB
cases identified in each step among COPD patients
selected by scenario 5 was demonstrated in Figure 2.
Comorbidities
Malignancy, diabetes mellitus, end-stage renal disease,
pneumoconiosis, liver cirrhosis, autoimmune diseases,
and acquired immunodeficiency disease were identified
according to our previous publication [19]. The low
income group was identified from the insurance status
and required the annual household income to be below
4500 US dollars [21].
Statistical analysis
The prescription duration of individual drugs was
converted from the claims data according to the
defined daily doses [22] and grouped according to
their pharmacological categories. Inhaled and systemic
corticosteroids were converted to equivalent doses of
budesonide 800 micrograms [23] and prednisolone in
grams [7], respectively.
Inter-group differences were compared using the
independent samples t-test for numerical variables
and chi-square test or Fisher’s exact test for categorical
variables as appropriate. Curves of time to commencement
of anti-TB treatment were generated using the Kaplan-
Meier method and were compared using the log-rank test.
The effects of COPD and other co-morbidities on the
risk of developing pulmonary TB were compared between
the COPD patients and control subjects using the Cox
proportional hazards model. Among the COPD patients,
a time-dependent Cox proportional hazard model was
applied to investigate the effect of co-morbidities and re-
spiratory medications on the risk of developing pulmonary
TB. The variables in the analysis included sex, age, the
prescribed dose of each class of respiratory medication,
and comorbidities. Each time-dependent drug prescription
was determined as the total prescribed dose from 360 days
to 90 days prior to each outcome event. An average dose
of ICS ≥ budesonide 800 microgram per day during the
period were defined as high-dose ICS.
The prevalence of smoking was much lower among
female COPD patients (24.2%) than that among the
general COPD patients (82.4%) in Taiwan [24,25]. To
explore the confounding by smoking, sub-population
analysis focusing on males and females separately
was conducted.
Basic model-fitting techniques, including variable
selection, goodness-of-fit, area under the receiver
operating characteristic curve, adjusted generalized R2
and regression diagnostics (residual analysis, detection
of influential cases, and check for multicollinearity),
were applied to assure the quality of the multivariate
analysis. Significance levels for entry and stay were set at
0.15. A two-sided p value of less than 0.05 was considered
significant. All analyses were performed using SAS software
(SAS Institute Inc., Cary, NC, USA).
Results
Among the 1,000,000 beneficiaries in the LHID 2005,
23,594 COPD cases were identified, and 47,188 non-
COPD subjects matched for age, gender, and timing of
entering the LHID 2005 were selected as the control
group. Their clinical characteristics are summarized in
Table 1. The mean age of the COPD cases was 54.5 ± 22.9
years with a male–female ratio of 1.6. The COPD group
had a significantly higher risk of developing TB than the
control group (2.9% vs. 1.2%, p < 0.001 by the chi-square
test), which also resulted in a shorter duration of follow-up
for the COPD group. Curves of time to commencement of
anti-TB treatment of the two groups were obvious sepa-
rated as calculated by the log-rank test (Figure 3). The most
common underlying comorbidities in the COPD group
were diabetes mellitus and malignancy. The COPD subjects
were more likely to have lung cancer and autoimmune
diseases. Furthermore, more COPD subjects had a low
income compared with the control subjects.
Cox proportional hazards regression analysis including
all of the variables listed in Table 1 for the 23,594 COPD
cases and the 47,188 control subjects revealed that
COPD was an independent risk factor for developing
pulmonary TB (hazard ratio = 2.468 [2.205 – 2.762])
(Table 2). We also found that increased age, male gender,
diabetes mellitus, end-stage renal disease, and liver cirrhosis
significantly increased the risk of developing pulmonary
TB. In the sub-population analyses focusing on males and
females separately, COPD remained an independent risk
factor associated with pulmonary TB in either genders with
a similar hazard ratio (Table 3).
Among the COPD cases selected under scenario 5,
those who subsequently developed pulmonary TB were
older (mean age 65.9 ± 11.4 years) and had a higher
male–female ratio (3.5) than those not developing TB
(Table 4). The mean interval between the index date of
COPD and diagnosis of TB was 4.6 ± 2.6 years. During
follow-up, the prescribed medications and number of
AE episodes are presented in Figure 4. The COPD
patients who subsequently developed TB received more
oral β-agonists and short-acting muscarinic antagonists
than those who did not develop TB, while the ICS dose
was similar in the two groups. The number of AE
episodes and consumption of OCS and LABA were
initially similar in the two groups, but later increased
more rapidly in those who subsequently developed TB.
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Univariate time-dependent Cox regression analysis for
the risk of developing pulmonary TB in the 23,594
COPD patients selected by using scenario 5 revealed
that age, male gender, diabetes mellitus, and low income
status were risk factors. OCS, oral β-agonists and ICS
dose-dependently increased the risk of developing pul-
monary TB (Table 5). In multivariate analysis, however,
the effect of ICS became obscured. Adding ICS into the
multivariate model produced a minimal effect on the other
co-variables. Although high-dose ICS was also significantly
associated with pulmonary TB in univariate analysis, it was
not an independent risk factor and had no effect on the
other co-variables in multivariate analysis if using this
categorical variable to replace the continuous variable –
ICS. The independent risk factors for TB and their hazard
ratios in the COPD patients selected under the six different
scenarios were similar (Figure 5, Tables 6 and 7).
Discussion
The present study has three important contributions
and findings. First, we found that COPD patients were
more likely to develop pulmonary TB than non-COPD
subjects under a wide variety of diagnostic scenarios for
COPD (scenarios 1 to 6, Figure 1). Second, ICS was not
a risk factor for developing active pulmonary TB among
COPD patients after considering important clinical
characteristics and other prescriptions. Third, COPD
patients who received higher doses of oral corticosteroids
Figure 2 Selection for TB patients. The number of TB cases
identified in each step among COPD patients selected by scenario 5.
Table 1 Characteristics of the COPD patients selected






Age (years) 54.5 ± 22.9 54.5 ± 22.9
Male 14,635 (62.0) 29,270 (62.0)
Developed TB 674 (2.9) 554 (1.2) <0.001#
Follow-up duration (years) 8.63 ± 2.54 8.71 ± 2.47 <0.001*
Diabetes mellitus 1,573 (6.7) 3126 (6.6) 0.831#
Malignancy 337 (1.4) 634 (1.3) 0.361#
other cancer 300 (1.3) 619 (1.3) 0.656#
lung cancer 37 (0.2) 15 (0.0) <0.001#
Autoimmune disease 65 (0.3) 61 (0.1) <0.001#
End-stage renal disease 37 (0.2) 82 (0.2) 0.604#
Liver cirrhosis 8 (0.0) 10 (0.0) 0.317#
Transplantation 4 (0.0) 6 (0.0) 0.740‡
Pneumoconiosis 2 (0.0) 0 (0.0) 0.111‡
HIV/AIDS 0 (0) 3 (0) 0.556‡
Low income 340 (1.4) 391 (0.8) <0.001#
HIV: human immunodeficiency virus, AIDS: acquired
immunodeficiency syndrome;
Data are shown as mean ± SD or No. (%) unless otherwise indicated.
* calculated by the independent-samples t test.
# calculated by the chi-square test.
‡ calculated by Fisher’s exact test.
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and oral β-agonists were more likely to develop active
pulmonary TB.
In univariate analysis, ICS dose-dependently increased
the risk of developing pulmonary TB. Given that COPD
is characterized by persistent and prominent airway
inflammation and progressive airflow limitation [26,27],
several randomized trials have demonstrated that ICS,
with or without concomitant use of LABA, could improve
pulmonary function and reduce AEs in patients with severe
COPD [15,28], although it was associated with an increased
risk of pneumonia [14,15]. Though the reported data
are inconsistent, there is increasing evidence that long-term
use of high-dose ICS may have systemic side effects such
as cataracts, adrenal suppression, skin changes, and
osteoporosis [29-31], and attenuate the adaptive immunity
of the airways [32]. The latter complication can be more
serious in TB-endemic areas, since suppression of the es-
sential defense mechanism against M. tuberculosis in the
airway and lung parenchyma may increase the risk of
active pulmonary TB [16,17,33].
Systemic corticosteroids have been demonstrated
to improve arterial hypoxemia and reduce the risk of
treatment failure and length of hospital stay in AE
of COPD [34,35]. In this situation, ICS alone may have
a similar benefit while minimizing the side effects of
systemic corticosteroids [36,37]. Therefore, ICS use in
COPD patients may reduce the overall requirement
of systemic corticosteroids by improving symptom control
and preventing AE and hospitalization [15], resulting in a
reduction in the risk of nosocomial exposure and the sub-
sequent development of active TB. This probably explains
Figure 3 Curves of time to commencement of anti-TB treatment. The curves of time to commencement of anti-TB treatment generated by
the Kaplan-Meier method among cases of chronic obstructive pulmonary disease (COPD) selected under scenario 5 and the control subjects.
Table 2 Cox regression analysis for risk factors of
pulmonary tuberculosis




Age (10 years) <0.001 1.464 1.406 1.524
Male <0.001 2.181 1.901 2.501
COPD <0.001 2.468 2.205 2.762
Diabetes mellitus 0.001 1.491 1.242 1.790
End-stage renal disease 0.037 2.602 1.059 6.393
Liver cirrhosis 0.007 6.958 1.682 28.776
Cox regression analysis for factors possibly associated with the development
of active tuberculosis in the 23,594 cases of chronic obstructive pulmonary
disease (COPD) selected under scenario 5 and the 47,188 non-COPD controls.
Table 3 Cox regression analysis for the impact of chronic
obstructive pulmonary disease (COPD) on risk of
developing pulmonary tuberculosis in male and female







All <0.001 2.468 2.205 2.762
Men <0.001 2.418 2.131 2.745
Women <0.001 2.681 2.098 3.426
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Table 4 Characteristics of the COPD patients selected under scenario 5 at index date
Not developing TB(N = 22,920) Developing TB(N = 674) p value
Age (years) 54.2 ± 23.1 65.9 ± 11.4 <0.001*
Follow-up duration (years) 8.6 ± 2.5 4.6 ± 2.6 <0.001*
Male 14,110 (61.6) 525 (77.9) <0.001#
Diabetes mellitus 1,566 (6.8) 55 (8.2) 0.179#
Malignancy 341 (1.5) 8 (1.2) 0.524#
lung cancer 36 (0.2) 1 (0.1) >0.999‡
other cancer 305 (1.3) 7 (1.0) 0.513#
Autoimmune disease 68 (0.3) 2 (0.5) >0.999‡
End-stage renal disease 35 (0.2) 2 (0.3) 0.285‡
Liver cirrhosis 8 (0.0) 0 (0) >0.999‡
Pneumoconiosis 2 (0.0) 0 (0) >0.999‡
Transplantation 4 (0.0) 0 (0) >0.999‡
HIV/AIDS 0 (0) 0 (0)
Low income 335 (1.5) 11 (1.6) 0.717#
HIV: human immunodeficiency virus, AIDS: acquired immunodeficiency syndrome; TB: tuberculosis;
Data are shown as mean ± SD or No. (%) unless otherwise indicated.
* calculated by the independent-samples t test.
# calculated by the chi-square test.
‡ calculated by Fisher’s exact test.
Figure 4 Associated medication consumption trends. The mean consumption (circle) and its 95% confidence interval (vertical error lines)
aggregated every 90 days following the index date for nine medications among cases of chronic obstructive pulmonary disease selected under
scenario 5. Oral and parenteral corticosteroids are presented as equivalent dose to prednisolone in milligrams, and the inhaled corticosteroids as
equivalent dose to budesonide. Other medications are presented as defined daily dose (DDD).
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the finding in the present study that the effect of ICS on
the risk of developing pulmonary TB became insignificant
when other factors, such as underlying comorbidities,
OCS and oral medications were concomitantly considered
in the multivariate model.
The finding that ICS use did not increase the risk of
active TB in COPD patients is in contrast with a previous
report from Taiwan [16] and the conclusion of a study
using the insurance databases of Quebec [17]. In both
studies, the average doses of OCS and ICS within a certain
period of time were used to determine the intensity of
drug exposure. Identification of COPD cases and the
corresponding index dates in the Quebec studies depended
on the prescription history of COPD medications. There-
fore, their results may have been biased because drug usage
usually varies with time, and a marked increase in drug
usage may have been recorded at the initial COPD diagno-
sis which then fluctuated with the natural course of disease
progression (similar to Figure 4). A better approach is to
use a time-dependent covariate to represent the usage of
each drug. In addition, although respiratory medications
other than ICS and OCS have never been reported to
increase the risk of TB, increased usage of these drugs as
well as an increasing number of AE episodes may imply
Table 5 Time-dependent Cox regression analysis for risk factors of pulmonary tuberculosis
Variables Univariate Multivariate Multivariate with ICS
p value HR (95% CI) p value HR (95% CI) p value HR (95% CI)
Age (per 10 years) <0.001 1.46 (1.38–1.54) <0.001 1.42 (1.35–1.50) <0.001 1.42 (1.35–1.50)
Male <0.001 2.28 (1.90–2.73) <0.001 2.06 (1.71–2.47) <0.001 2.06 (1.71–2.47)
Diabetes mellitus 0.001 1.54 (1.26–1.88) 0.035 1.24 (1.02–1.52) 0.034 1.25 (1.02–1.53)
Oral corticosteroids* <0.001 1.29 (1.15–1.44) 0.011 1.18 (1.04–1.33) 0.017 1.17 (1.03–1.32)
Oral β-agonists (per 30 DDD) <0.001 1.06 (1.04–1.07) 0.005 1.05 (1.02–1.09) 0.006 1.05 (1.01–1.09)
ICS# 0.020 1.01 (1.00–1.02) 0.245 1.01 (0.99–1.03)
Low income <0.001 2.04 (1.36–3.06) 0.004 1.82 (1.21–2.73) 0.004 1.82 (1.21–2.74)
HR: hazard ratio; DDD: defined daily dose; CI: confidence interval; ICS: inhaled corticosteroids. *Oral corticosteroids were converted to the equivalent dose of
prednisolone 1 gram. #ICS were converted to the equivalent dose of budesonide 24 mg.
Time-dependent Cox regression analysis for factors possibly associated with the development of active tuberculosis in cases of chronic obstructive pulmonary
disease selected under scenario 5.
Figure 5 Hazard ratios for developing tuberculosis. Hazards ratio (marked circle) and its 95% confidence interval (horizontal error lines) of
each independent risk factor for developing active tuberculosis (TB) among cases of chronic obstructive pulmonary disease (COPD) selected
under different scenarios.
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more severe COPD, requiring more frequent out-patient
visits and hospitalization. These may increase the risk of in-
fection by Mycobacterium tuberculosis and the subsequent
development of active TB [38,39]. However, in the two
studies, usage of respiratory medication and the number of
AEs were not considered in the analysis.
The findings that age, male gender, diabetes, and
receiving oral corticosteroids were risk factors for TB
is consistent with the findings in prior literature [2,40,41].
Of note, the present study is the only cohort study
conducted in a large general population controlled for a
broad range of comorbidities, pharmacological and
socioeconomic confounders in a time-dependent analysis.
The frequency of AEs, which served as surrogate factors
representing COPD severity and the risk of nosocomial
TB exposure, remained significantly associated with the
development of TB after adjusting for baseline clinical
characteristics and the effect of corticosteroids in COPD
patients selected under scenarios 1 and 2. However, the
frequency of AEs became insignificant under scenarios 3 to
6, probably due to the reduced sample size. Furthermore,
the association of increased use of oral beta-agonists and
muscarinic antagonists to active TB suggests that the
deterioration in pulmonary symptoms requiring increased
medication could be a reflection of the development and
progression of pulmonary TB. Therefore in TB endemic
areas one should suspect TB when patients with chronic
respiratory diseases deteriorate.
Smoking, the most important risk factor for COPD,
has also been demonstrated to be associated with pulmon-
ary TB [42]. Because the smoking status is not available in
the NHIRD, it is possible that some of the effects of male
gender on the development of pulmonary TB observed in
present study are through the effect of smoking. However,
if that were true, the hazard ratio of COPD for subsequent
development of pulmonary TB should be higher in male
sub-population than that in female counterpart since the
prevalence of smoking was much lower among female
COPD patients (24.2%) than that among general COPD
patients (82.4%) in Taiwan [24,25]. The findings that COPD
has a similar impact on the development of pulmonary TB
in both genders suggest that the effect of COPD on the risk
of pulmonary TB observed in the present study should not
be completely attributed to smoking.
There are several limitations to this study. First,
mycobacteriological results, pulmonary function tests
Table 6 Time-dependent Cox regression analysis for risk factors of pulmonary tuberculosis
Variables Scenario 1 Scenario 2 Scenario 3
p value HR (95% CI) p value HR (95% CI) p value HR (95% CI)
Age (10 years) <.0001 1.489 (1.436–1.545) <.0001 1.385 (1.330–1.443) <.0001 1.430 (1.363–1.501)
Male <.0001 2.222 (1.929–2.559) <.0001 2.145 (1.845–2.494) <.0001 2.056 (1.741–2.427)
Diabetes mellitus <.0001 1.456 (1.234–1.719) <.0001 1.416 (1.189–1.687) 0.0163 1.256 (1.043–1.513)
Oral corticosteroids (g) 0.0004 1.171 (1.073–1.279) 0.0028 1.157 (1.051–1.273) <.0001 1.185 (1.097–1.281)
Oral beta-agonists (30 DDD) 0.0007 1.056 (1.023–1.090) 0.0115 1.071 (1.015–1.130) 0.0029 1.051 (1.017–1.087)
Inhaled SAMA* (30 DDD) 0.001 1.043 (1.017–1.069) 0.0053 1.039 (1.011–1.068)
Acute exacerbations 0.0008 1.026 (1.011–1.042) 0.0127 1.021 (1.004–1.038)
Low income 0.0027 1.8 (1.225–1.644)
HR: hazard ratio, CI: confidence interval, SAMA: short-acting muscarinic antagonists, DDD: defined daily dose
Time-dependent Cox regression analysis for the factors possibly associated with the development of active tuberculosis in cases of chronic obstructive pulmonary
disease selected under scenarios 1–3.
Table 7 Time-dependent Cox regression analysis for risk factors of pulmonary tuberculosis
Variables Scenario 4 Scenario 5 Scenario 6
p value HR (95% CI) p value HR (95% CI) p value HR (95% CI)
Age (10 years) <.0001 1.431 (1.360–1.505) <.0001 1.420 (1.348–1.497) <.0001 1.248 (1.159–1.343)
Male <.0001 2.073 (1.736–2.477) <.0001 2.058 (1.714–2.471) <.0001 2.113 (1.752–2.549)
Diabetes mellitus 0.0483 1.222 (1.001–1.490) 0.0349 1.243 (1.016–1.522)
Oral corticosteroids (g) 0.0043 1.247 (1.044–1.261) 0.0107 1.176 (1.038–1.331) 0.0404 1.147 (1.006–1.307)
Oral beta-agonists (30 DDD) 0.0011 1.054 (1.021–1.088) 0.0046 1.050 (1.015–1.086) 0.009 1.055 (1.013–1.098)
Low income 0.0031 1.828 (1.226–2.725) 0.004 1.819 (1.210–1.734) 0.0018 1.914 (1.273–2.879)
HR: hazard ratio, CI: confidence interval, DDD: defined daily dose.
Time-dependent Cox regression analysis for the factors possibly associated with the development of active tuberculosis in cases of chronic obstructive pulmonary
disease selected under scenarios 4–6.
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and radiological findings were not available. Therefore, it
is impossible to confirm the diagnosis and determine the
severity of pulmonary TB and COPD. However, by using
different scenarios to select COPD cases, our analysis
showed that the identified risk factors for TB were very
similar, if not completely the same, in a large and diverse
population. We believe our conclusions can be applied
to the management of COPD since the findings were
generated from a national insurance database, which is a
record of medical practice in the real world. Second,
because COPD patients in Taiwan have a high prevalence
of pulmonary colonization or infection by non-tuberculous
mycobacteria (NTM), a very long duration of anti-TB
treatment was chosen as one of the diagnostic criteria for
pulmonary TB in the present study to exclude patients
who received empiric treatment for TB and was later
proven as NTM or other pulmonary diseases. However, by
applying the very strict definition of TB, the incidence of
active TB may have been underestimated because of
default and early mortality. Third, the interpretation of the
causal relationship between COPD and TB based on their
temporality is difficult because COPD may be a complica-
tion of TB [43,44]. However, this may not be a serious con-
cern because the trend of an increasing risk of TB persisted
even after 10 years (Figure 3). Lastly, the estimation of drug
exposure may have been biased since information on drug
adherence was not available in the national insurance
database. Further large-scale prospective studies are needed
to address these issues.
Conclusion
COPD patients are at high risk of developing pulmonary
TB, especially those frequently receiving oral corticosteroids
and oral β-agonists. Although ICS therapy has been shown
to predispose COPD patients to pneumonia in large ran-
domized clinical trials, it does not increase the risk of TB in
real world practice. The selection criteria for COPD and
TB defined in the present study may be helpful in further
research using health insurance databases.
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